|
1
|
Boncheva V, Bonney SA, Brooks SE, et al:
New targets for the immunotherapy of colon cancer-does reactive
disease hold the answer? Cancer Gene Ther. 20:157–168. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang N, Li X, Wu CW, et al: microRNA-7 is
a novel inhibitor of YY1 contributing to colorectal tumorigenesis.
Oncogene. 32:5078–5088. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dassow H and Aigner A: MicroRNAs (miRNAs)
in colorectal cancer: from aberrant expression towards therapy.
Curr Pharm Des. 19:1242–1252. 2013.PubMed/NCBI
|
|
5
|
Dong Y, Zhao J, Wu CW, et al: MiR-133a
activates the p53/p21 pathway and functions as a tumor suppressor
in colorectal cancer by repressing RFFL. Mol Cancer Res.
11:1051–1060. 2013. View Article : Google Scholar
|
|
6
|
Yu Y, Sarkar FH and Majumdar AP:
Down-regulation of miR-21 induces differentiation of chemoresistant
colon cancer cells and enhances susceptibility to therapeutic
regimens. Transl Oncol. 6:180–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
He JF, Luo YM, Wan XH and Jiang D:
Biogenesis of MiRNA-195 and its role in biogenesis, the cell cycle,
and apoptosis. J Biochem Mol Toxicol. 25:404–408. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang X, Yu J, Yin J, Xiang Q, Tang H and
Lei X: MiR-195 regulates cell apoptosis of human hepatocellular
carcinoma cells by targeting LATS2. Pharmazie. 67:645–651.
2012.PubMed/NCBI
|
|
9
|
Mao JH, Zhou RP, Peng AF, et al:
microRNA-195 suppresses osteosarcoma cell invasion and migration
in vitro by targeting FASN. Oncol Lett. 4:1125–1129.
2012.PubMed/NCBI
|
|
10
|
Ding J, Huang S, Wang Y, et al:
Genome-wide screening reveals that miR-195 targets the TNF-α/NF-κB
pathway by down-regulating IκB kinase alpha and TAB3 in
hepatocellular carcinoma. Hepatology. 58:654–666. 2013.PubMed/NCBI
|
|
11
|
Yang G, Wu D, Zhu J, et al: Upregulation
of miR-195 increases the sensitivity of breast cancer cells to
Adriamycin treatment through inhibition of Raf-1. Oncol Rep.
30:877–889. 2013.PubMed/NCBI
|
|
12
|
Li Z, Qu L, Dong Q, et al: Overexpression
of CARMA3 in non-small-cell lung cancer is linked for tumor
progression. PLoS One. 7:e369032012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao T, Miao Z, Wang Z, et al: CARMA3
overexpression accelerates cell proliferation and inhibits
paclitaxel-induced apoptosis through NF-κB regulation in breast
cancer cells. Tumour Biol. 34:3041–3047. 2013.PubMed/NCBI
|
|
14
|
Miao Z, Zhao T, Wang Z, et al: CARMA3 is
overexpressed in colon cancer and regulates NF-κB activity and
cyclin D1 expression. Biochem Biophys Res Commun. 425:781–787.
2012.PubMed/NCBI
|
|
15
|
Feng X, Miao G, Han Y and Xu Y: CARMA3 is
overexpressed in human glioma and promotes cell invasion through
MMP9 regulation in A172 cell line. Tumour Biol. July 27–2013.(Epub
ahead of print).
|
|
16
|
Callegari E, Elamin BK, Sabbioni S,
Gramantieri L and Negrini M: Role of microRNAs in hepatocellular
carcinoma: a clinical perspective. Onco Targets Ther. 6:1167–1178.
2013.PubMed/NCBI
|
|
17
|
Chou J, Shahi P and Werb Z:
microRNA-mediated regulation of the tumor microenvironment. Cell
Cycle. 12:3262–3271. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bienertova-Vasku J, Sana J and Slaby O:
The role of microRNAs in mitochondria in cancer. Cancer Lett.
336:1–7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hammoud SS, Cairns BR and Jones DA:
Epigenetic regulation of colon cancer and intestinal stem cells.
Curr Opin Cell Biol. 25:177–183. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Piepoli A, Tavano F, Copetti M, et al:
Mirna expression profiles identify drivers in colorectal and
pancreatic cancers. PLoS One. 7:e336632012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X, Wang J, Ma H, Zhang J and Zhou X:
Downregulation of miR-195 correlates with lymph node metastasis and
poor prognosis in colorectal cancer. Med Oncol. 29:919–927. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu L, Chen L, Xu Y, Li R and Du X:
microRNA-195 promotes apoptosis and suppresses tumorigenicity of
human colorectal cancer cells. Biochem Biophys Res Commun.
400:236–240. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qu J, Zhao L, Zhang P, et al: MicroRNA-195
chemosensitizes colon cancer cells to the chemotherapeutic drug
doxorubicin by targeting the first binding site of BCL2L2 mRNA. J
Cell Physiol. March 22–2013.(Epub ahead of print).
|
|
24
|
Wu GL, Yuan JL, Huang XD, et al:
Evaluating the expression of CARMA3 as a prognostic tumor marker in
renal cell carcinoma. Tumour Biol. 34:3431–3435. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rehman AO and Wang CY: CXCL12/SDF-1 alpha
activates NF-kappaB and promotes oral cancer invasion through the
Carma3/Bcl10/Malt1 complex. Int J Oral Sci. 1:105–118. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun J: CARMA3: A novel scaffold protein in
regulation of NF-κB activation and diseases. World J Biol Chem.
1:353–361. 2010.
|
|
27
|
Dilly AK, Ekambaram P, Guo Y, et al:
Platelet-type 12-lipoxygenase induces MMP9 expression and cellular
invasion via activation of PI3K/Akt/NF-κB. Int J Cancer.
133:1784–1791. 2013.PubMed/NCBI
|
